Loading company…
Protai uses artificial intelligence to support drug discovery through analysis of proteins and disease processes.
Founded in 2021 and based in Tel Aviv, Israel, Protai develops an AI platform that maps disease processes at the protein level to support drug discovery. Its co-founders are Eran Seger and Kirill Prevzner. In January 2022, the company raised USD 8 million in seed funding co-led by Grove Ventures and Pitango Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in